

ZIOPHARM ONCOLOGY INC
Form SC 13D/A
January 25, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Amendment No. 3)*
Under the Securities Exchange Act of 1934

ZIOPHARM ONCOLOGY, INC.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

98973P101

(CUSIP Number)

Third Security, LLC
1881 Grove Avenue
Radford, Virginia 24141
Attention: Marcus E. Smith, Esq.
(540) 633-7900

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

Copy to:
Intrexon Corporation
Attention: Legal
20358 Seneca Meadows Parkway
Germantown, Maryland 20876
(301) 556-9809

January 20, 2012

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of

this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box o .

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 98973P101

Page 3 of 7

- 1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Intrexon Corporation
I.R.S. IDENTIFICATION NO.: 26-0084895

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF GROUP
(a)
(b)

- 3 SEC USE ONLY

- 4 SOURCE OF FUNDS

WC

- 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) OR 2(e)

0

- 6 CITIZENSHIP OR PLACE OF ORGANIZATION

Virginia

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7 SOLE VOTING POWER 0 8 SHARED VOTING POWER 9,896,236 9 SOLE DISPOSITIVE POWER 0 10 SHARED DISPOSITIVE POWER 9,896,236
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	9,896,236
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	12.7%
14 TYPE OF REPORTING PERSON	CO

CUSIP No. 98973P101

Page 4 of 7

This Amendment No. 3 (the "Amendment") amends and supplements the Statement on Schedule 13D, dated January 12, 2011 and filed on January 20, 2011, as amended by Amendment No. 1 dated February 3, 2011 and filed on February 11, 2011, and Amendment No. 2 dated August 9, 2011 and filed on August 16, 2011 (the "Original Schedule 13D"), relating to the Common Stock, par value \$0.001 per share (the "Common Stock"), of ZIOPHARM Oncology, Inc., a Delaware corporation (the "Company"). Mr. Randal J. Kirk ("Mr. Kirk") and Intrexon Corporation, a Virginia corporation ("Intrexon" and, together with Mr. Kirk, the "Reporting Persons"), are filing this Amendment to disclose the acquisition by Intrexon, an affiliate of Mr. Kirk, of 1,923,075 shares of Common Stock in a public offering. Mr. Kirk could be deemed to have indirect beneficial ownership of the shares of Common Stock directly beneficially owned by Intrexon and Kapital Joe, LLC ("Kapital Joe"), an affiliate of Mr. Kirk that also owns shares of Common Stock disclosed herein.

Except as set forth below, there are no changes to the information set forth in the Original Schedule 13D.

CUSIP No. 98973P101

Page 5 of 7

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows:

Intrexon utilized its working capital to purchase the 1,923,075 shares of Common Stock purchased in a public offering by the Company. In addition, between August 18, 2011 and August 23, 2011, Kapital Joe utilized its working capital to purchase 499,940 shares of Common Stock through open market purchases for an aggregate purchase price of approximately \$2.46 million.

Item 5. Interest in Securities of the Issuer.

Items 5(a) and (b) of the Original Schedule 13D are hereby amended and restated to read in their entirety as follows:

(a) and (b) See Items 11 and 13 of the cover pages to this Statement for the aggregate number of shares and percentage of issued and outstanding shares of Common Stock of the Company owned by the Reporting Persons. The percentage ownership is calculated based on 68,451,324 shares of Common Stock issued and outstanding as of October 28, 2011, based upon the number of shares disclosed by the Company as of such date in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2011, plus 9,650,000 shares issued in the January 20, 2012 public stock offering and 8,334 shares of Common Stock issuable upon exercise of stock options directly owned by Mr. Kirk that are currently exercisable.

Reporting Person	Amount of Common Stock Beneficially Owned	Percent of Class		Sole Power to Vote or Direct the Vote	Shared Power to Vote or Direct the Vote	Sole Power to Dispose or to Direct the Disposition	Shared Power to Dispose or to Direct the Disposition
Randal J. Kirk	11,293,609	14.5	%	50,911	11,242,698(1)	50,911	11,242,698 (1)
Intrexon Corporation	9,896,236	12.7	%	—	9,896,236	—	9,896,236

(1) Includes 9,896,236 shares of Common Stock held by Intrexon and 1,346,462 shares of Common Stock held by Kapital Joe.

Mr. Kirk could be deemed to have indirect beneficial ownership of the shares of Common Stock directly beneficially owned by Intrexon and Kapital Joe.

Item 5(c) of the Original Schedule 13D is hereby supplemented and amended as follows:

(c) Other than the purchases disclosed herein and a restricted stock grant in December 2011 in connection with Mr. Kirk's service on the Company's Board of Directors, the Reporting Persons have not engaged in any transactions in shares of Common Stock since the filing of Amendment No. 2 with the Securities and Exchange Commission on August 16, 2011.

CUSIP No. 98973P101

Page 6 of 7

Item 7.

Material to be Filed as Exhibits.

ExhibitJoint Filing Agreement, dated as of January 25, 2012, by and between Mr. Kirk and Intrexon

1

CUSIP No. 98973P101

Page 7 of 7

SIGNATURES

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Date: January 25, 2012

/s/ Randal J. Kirk
Randal J. Kirk

INTREXON CORPORATION

By: /s/ Randal J. Kirk
Randal J. Kirk
Chief Executive Officer

EXHIBIT INDEX

Exhibit Joint Filing Agreement, dated as of January 25, 2012, by and between Mr. Kirk and Intrexon
1
